Safety and Efficacy Updates of Specific DOAC Reversal Agents: New Data and Real-World Evidence, featuring Patient Cases
Portola Pharmaceuticals, Inc.
Faculty Presenter
Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC
Professor of Pharmacy Practice
MCPHS University School of Pharmacy
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Program Description
Prescribing practices have led direct oral anticoagulants (DOACs) to be used extensively in patients who require anticoagulant therapy for treatment or prophylaxis of thromboembolic events. But patients and clinicians may encounter emergent situations that necessitate the rapid reversal of anticoagulation effects of DOACs. Pharmacists are especially important when DOAC reversal is warranted, as these situations require proper and timely administration of reversal agents. Two specific reversal agents have been recommended in the guidelines, andexanet alfa and idarucizumab, and it is imperative for pharmacists to understand the safe and appropriate role of each of these therapies. In addition to discussing recent data and real-world utilization, expert faculty will review cases of patients with DOAC-related bleeding and share strategies to support clinical decisions in the health-system setting.
Target audience: Health-system pharmacists
Type of activity: Application
Release date: December 23, 2020
Expiration date: June 23, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the most recent guidelines and recommendations for the reversal of major bleeding associated with the use of direct oral anticoagulants (DOACs)
- Examine up-to-date clinical data and real-world evidence of the safety outcomes of specific reversal agents and prothrombin complex concentrates for reversing life-threatening DOAC-related bleeding
- Identify the role of health-system pharmacists, formulary committee members, and pharmacy directors in improving clinical outcomes and decreasing mortality rates in patients being treated for major bleeding related to the use of DOACs
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-396-H01-P. The activity is available for CE credit through June 23, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: Janssen Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc.
Spouse: Employee at Amgen
Gabriel Fontaine, PharmD, MBA, BCPS, served as a medical reviewer and has the following conflict to disclose:
- Consultant and Speakers Bureau: Portola Pharmaceuticals, Inc.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Brianna Schauer, MBA, PMP; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
